Abstract Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin wound therapy, incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, which may be generalized to the other tissues healing
25 , 26 , 27 , 28 , 29 , 30 The safety profile of semaglutide is well established through large clinical trials in individuals with T2D and with obesity 31 , 32
While weight loss results may vary, studies have shown that individuals taking semaglutide experience significant improvements in their overall health, including lower blood sugar levels and decreased risk of heart disease
Exposure to temperatures outside the recommended range can break down semaglutides protein structure, reducing its ability to lower blood sugar levels